Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Virax Biolabs Group Ltd. Class A ( (VRAX) ) is now available.
On March 11, 2026, Virax Biolabs Group Ltd. convened its 2025 annual shareholder meeting in Glasgow, but the session was adjourned due to lack of quorum after only 15.74% of eligible shares were represented. In line with its articles of association, the company rescheduled the meeting to March 18, 2026, when those present in person or by proxy were deemed a quorum despite representing just 15.78% of voting shares.
At the reconvened meeting on March 18, 2026, shareholders ratified the appointment of Reliant CPAs PC as auditor for the fiscal year ending March 31, 2026, and re-elected five directors to serve until the next annual meeting. Investors also approved a significant share consolidation, an updated memorandum and articles of association to reflect revised authorized share capital, and a 2026 Equity Incentive Plan reserving 2,000,000 ordinary shares, moves that streamline Virax’s capital structure and support future employee and executive compensation programs.
The most recent analyst rating on (VRAX) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Virax Biolabs Group Ltd. Class A stock, see the VRAX Stock Forecast page.
More about Virax Biolabs Group Ltd. Class A
Virax Biolabs Group Ltd. is a U.K.-based life sciences company operating out of BioCity Glasgow, focusing on biotechnology and diagnostics. The company develops and commercializes medical and laboratory products aimed at infectious disease detection and immune profiling, targeting global healthcare and research markets.
Average Trading Volume: 295,940
Technical Sentiment Signal: Sell
Current Market Cap: $1.5M
See more insights into VRAX stock on TipRanks’ Stock Analysis page.